ARTICLE | Clinical News
Rilpivirine regulatory update
September 6, 2010 7:00 AM UTC
Johnson & Johnson's Tibotec Pharmaceuticals Ltd. division submitted an MAA to EMA for rilpivirine (TMC278) for use in combination with other antiretrovirals to treat HIV-1 infection in adults. Rilpivi...